Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pacemakers and defibrillators

Implantable pacemakers and defibrillators are electronic devices that detect cardiac electrical activity and deliver therapies according to settings tailored to the patient's disease and needs. A pacemaker prevents or corrects an inadequate heart rate and can coordinate the relationship between atrial and ventricular activation. An implantable defibrillator, or ICD, identifies certain ventricular tachyarrhythmias and treats them with antitachycardia pacing or shocks, depending on the system's capabilities. Cardiac resynchronization coordinates ventricular activation in selected patients and may provide pacing alone, as CRT-P, or pacing combined with defibrillation, as CRT-D.

These functions are not interchangeable. A conventional pacemaker does not directly protect against ventricular fibrillation; a conventional subcutaneous defibrillator does not offer the same continuous pacing and antitachycardia pacing capabilities as a transvenous system. Moreover, preventing sudden death is not the same as treating the heart disease that causes the arrhythmias. Implantation therefore forms part of a care pathway that includes diagnosis of the underlying substrate, drug therapy, possible ablation, control of reversible factors and periodic assessment of the balance between benefit and risk.

The use of these systems is influenced by population ageing, the prevalence of conduction disorders, survival after cardiac events and access to care. The EHRA consensus on implantation technique cites European data showing that, over the decade examined in the 2017 White Book, pacemaker implantations increased by 20% and ICD implantations by 44%. These are historical indicators of expanding use, not measures of current prevalence or an individual patient's needs. The risk of complications also varies with the type of device, number of components, first implantation versus revision and patient characteristics.

Modern selection considers the long-term treatment pathway. A young patient who will require pacing for decades faces different issues from a frail patient with limited life expectancy; someone who only needs protection against ventricular arrhythmias does not automatically require an atrial lead. The availability of leadless systems, extravascular defibrillators and conduction system pacing broadens the options but does not make one technology preferable for every indication. The outcome depends on appropriate selection and the ability to maintain effective treatment during follow-up.

Pathophysiological basis and rationale for treatment

The normal rhythm originates from the automaticity of the sinus node, spreads through the atria and reaches the ventricles via the atrioventricular node, bundle of His and Purkinje network. Spontaneous diastolic depolarization of pacemaker cells depends on the interaction between membrane ion currents and intracellular calcium cycling; autonomic activity modifies its rate. Specialized conduction, in turn, enables rapid, coordinated ventricular activation. A device can replace some impaired functions, but it does not automatically recreate normal physiology in its entirety: the site and sequence of impulses have specific haemodynamic effects.

Sinus node dysfunction can result from degeneration and fibrosis of nodal and atrial tissue, infiltrative diseases, genetic conditions or other cardiac processes. Drugs, metabolic disturbances and autonomic modulation may cause or aggravate bradycardia without permanent nodal damage. The clinical problem is not merely a low resting rate: pauses, alternation between atrial tachyarrhythmias and bradycardia, and an inability to increase heart rate adequately during exercise may reduce cardiac output. Because stroke volume cannot always compensate for this reduction, fatigue, exercise intolerance or cerebral hypoperfusion may occur.

Atrioventricular block interrupts or slows conduction from the atria to the ventricles. Nodal and infra-Hisian sites differ in their behaviour and risks. Degeneration of the conduction system, ischaemia, inflammatory or infiltrative diseases, genetic heart disease and damage following procedures may cause persistent impairment; medications and acute conditions may cause potentially reversible forms. In advanced block, perfusion depends on the stability and rate of the escape rhythm. Pacing prevents ventricular function from depending on inadequate or unpredictable automaticity.

Ventricular arrhythmias have a different treatment rationale. A post-infarction or non-ischaemic scar can create slow-conduction pathways sustaining re-entry and monomorphic tachycardias. Acute ischaemia, electrical instability and certain ion-channel disorders can promote polymorphic tachycardia or fibrillation. Disorganized contraction can rapidly abolish cardiac output and cause cardiac arrest. An ICD terminates an arrhythmia when it is detected and amenable to treatment, but does not eliminate the scar, channelopathy or other factors that allowed it to arise.

Antitachycardia pacing uses sequences of impulses faster than the tachycardia to enter and interrupt the re-entrant circuit. It is particularly useful for many monomorphic ventricular tachycardias and may avoid a shock; effectiveness depends on rate, mechanism and substrate characteristics. A shock, by contrast, generates an electric field capable of interrupting arrhythmic activity by depolarizing a critical mass of tissue. Success depends on energy, vector, impedance, component positioning and myocardial conditions, not merely on delivery of a discharge.

Ventricular dyssynchrony is another therapeutic target. With left bundle branch block or certain forms of right ventricular pacing, myocardial regions are activated and contract at different times. Part of the work is dissipated in deforming segments that are still relaxed rather than ejecting blood; filling, mitral regurgitation and wall stress may worsen. CRT seeks to reduce these delays through coordinated pacing, whereas conduction system pacing aims to recruit the specialized pathways more directly. Benefit depends on whether dyssynchrony genuinely contributes to the patient's dysfunction.

Very frequent ventricular pacing can have consequences even in a heart that was initially less severely affected. Guidelines on physiologic pacing regard a pacing burden in the range of 20–40% as clinically relevant when assessing risk and alternatives, without defining it as a deterministic threshold for disease. Ventricular function, QRS duration, pacing site and comorbidities influence susceptibility. The BLOCK-HF trial demonstrated the value of biventricular versus right ventricular pacing in selected patients with atrioventricular block and systolic dysfunction, showing that the mode of heart-rate support can affect outcomes.

The rationale for implantation also includes competing risk. If the likelihood of death from advanced heart failure, cancer or other causes is high, preventing one mode of death may yield only limited overall benefit. In sinus node dysfunction the advantage of a pacemaker is primarily symptomatic; in advanced block it may also improve prognosis; an ICD targets arrhythmic death; and CRT may improve function, symptoms, hospitalizations and survival. These aims should be made explicit before choosing the system.

Device architecture, sensing and pacing modes

The generator contains a battery, control circuitry, memory and communication systems. ICDs also have circuits to store and release the energy required for high-voltage therapy. Leads connect the generator to sensing and pacing sites and comprise conductors, insulation and electrodes; defibrillation leads include dedicated shock coils. In conventional systems, the generator is housed in a subcutaneous or deeper pocket while the leads reach the heart through the venous circulation. In epicardial systems, contact with the heart is established surgically.

Capture occurs when an impulse produces effective depolarization. The threshold is expressed in relation to both pulse amplitude and duration: a voltage value without the corresponding duration does not fully describe performance. The strength–duration relationship allows a longer pulse to compensate partly for lower amplitude, with implications for energy consumption. Output is programmed with an adequate safety margin; automatic algorithms can adjust it provided their operation is appropriate for the lead type and has been assessed in the patient.

Sensing enables the device to recognize intrinsic signals and coordinate its response. Intracardiac signal amplitude and the programmed sensitivity setting are distinct concepts: a lower sensing threshold in millivolts generally makes the system more sensitive. Excessive sensitivity can promote detection of noise, myopotentials or far-field signals; insufficient sensitivity can miss genuine depolarizations. In defibrillators, dynamic sensing systems must also detect rapid ventricular signals of variable amplitude, such as those occurring during fibrillation.

Bipolar and unipolar configurations differ in the electrical circuit used. In bipolar sensing, the measurement is made between relatively close electrodes; in a unipolar configuration, the generator may form part of the circuit, increasing the distance between poles and sensitivity to certain extracardiac signals. Impedance measures opposition to current flow and helps monitor integrity, but must be interpreted in relation to the system and changes over time. An isolated value cannot replace examination of thresholds, sensing, noise and temporal trends.

The pacing mode code describes the chamber paced, chamber sensed, response to sensing and other functions. In VVI, the ventricle is paced and sensed, and a pacing impulse is inhibited when an appropriate intrinsic event occurs. In AAI, the same principle applies to the atrium and requires adequate atrioventricular conduction. In DDD, both chambers are managed, allowing the ventricular response to be coordinated with atrial events within programmed limits. The letter R indicates a sensor-based rate-adaptive function. The mode is chosen according to the disorder being corrected and the expected rhythm, not by assuming that more letters always mean better therapy.

In dual-chamber operation, the atrioventricular interval governs the time between an atrial event and ventricular pacing when recognized intrinsic conduction does not occur. An excessively short interval may increase ventricular pacing and impair filling physiology; an excessively long interval can also have haemodynamic consequences. Settings must account for conduction, rate and the need for resynchronization. Algorithms that minimize unnecessary ventricular pacing may be beneficial but are not universally appropriate in every patient with conduction disease.

Blanking and refractory periods prevent certain signals from being interpreted inappropriately. After a ventricular event, atrial refractoriness helps prevent a retrograde P wave from being detected as a signal to track. If ventriculoatrial conduction and programming permit, a circuit can develop in which the ventricle retrogradely activates the atrium and the device then paces the ventricle again. This is the classic mechanism of pacemaker-mediated tachycardia. Understanding timing intervals is therefore essential to distinguish physiology, algorithm behaviour and arrhythmia.

The upper tracking rate limit prevents every rise in atrial rate from being transmitted without limit to the ventricle. When sinus rate increases beyond the programmed tracking capacity, Wenckebach-like behaviour or functional 2:1 block may occur, also depending on the atrioventricular interval and atrial refractory period. During atrial fibrillation or flutter, mode switching may move the device into a mode that does not rapidly track atrial activity. These behaviours can explain exercise-related symptoms and should be recognized before suspecting device breakage.

Rate-response sensors estimate metabolic demand from signals such as movement and ventilation, depending on the model. Thresholds, slopes and response times must be adapted to the patient's functional profile. A poorly responsive sensor may leave the rate inadequate during exertion; an excessive response may cause perceived tachycardia even without an arrhythmia. Assessment during real-life activity or exercise testing can reveal problems that do not emerge during resting interrogation.

In an ICD, detection zones classify rhythms by rate and duration and, when available, also use discriminators based on morphology, regularity and the atrioventricular relationship. Detection periods long enough to allow spontaneous termination of many self-limiting arrhythmias, and higher thresholds can reduce treatment of supraventricular tachycardias. These advantages must be balanced against the need to detect the patient's clinical ventricular tachycardias, which may be relatively slow. Stored electrograms allow verification of classification accuracy and treatment effectiveness.

Clinical manifestations and pre-implantation assessment

Assessment begins with symptoms and their relationship to cardiac rhythm. In suspected bradycardia, clinicians look for fatigue, reduced exercise tolerance, dizziness, presyncope, syncope and worsening heart failure. Circumstances, posture, prodromes, duration and recovery are clarified, and eyewitness accounts obtained when possible. Palpitations followed by a perceived pause or presyncope may suggest bradycardia–tachycardia syndrome, but diagnosis requires documentation. A low rate in an asymptomatic athlete has a different significance from bradycardia associated with hypoperfusion.

For ventricular arrhythmic risk, relevant features include resuscitated cardiac arrest, documented tachycardia, sudden syncope, ischaemic heart disease, cardiomyopathy and a family history of sudden death. Age at onset, exercise, stress, fever and medications may point towards specific substrates. Previous myocardial infarctions, revascularization procedures, myocarditis, infiltrative diseases and treatments are also reviewed. Suspecting a transient cause cannot rest solely on the presence of a potentially reversible factor: it is necessary to determine whether that factor adequately explains the event and whether a high-risk substrate persists.

Physical examination includes pulse rate and regularity, blood pressure including standing measurements when appropriate, signs of hypoperfusion and heart failure, murmurs and relevant extracardiac findings. Peripheral bradycardia must be confirmed electrically because premature beats without an effective peripheral pulse can mimic a slow rate. Jugular venous distension, pulmonary congestion and oedema help establish the haemodynamic context. The examination must also identify local or systemic conditions affecting implant feasibility, including active infection, previously used vascular access and fragile skin.

The 12-lead ECG characterizes rhythm, intervals, probable location of conduction disease, QRS morphology and signs of heart disease. When symptoms are intermittent, Holter monitoring, prolonged recordings or an implantable monitor are selected according to episode frequency. Symptom–rhythm correlation is particularly important in sinus node dysfunction and unexplained syncope. Conversely, in documented, nonreversible advanced atrioventricular block, the risk may justify pacing even without a simultaneous recording of syncope.

Evaluation of reversible causes includes medication review, electrolytes, thyroid function when indicated, ischaemia and relevant acute conditions. Nocturnal bradycardia may warrant assessment for sleep-disordered breathing. After certain procedures or with inflammatory disease, conduction may recover and the observation period is tailored to risk and the availability of temporary support. However, unsafe delay should not be prolonged in the presence of unstable block or the absence of a reliable escape rhythm.

Echocardiography determines ventricular function, valve disease, chamber dimensions and possible structural causes. Ejection fraction influences the choice between conventional pacing, physiologic strategies and ICD protection, but must be interpreted in light of disease stage and treatment received. Magnetic resonance imaging can identify fibrosis, scarring, inflammation or infiltration and aid arrhythmic risk stratification. Where appropriate, coronary assessment, genetic testing, electrophysiological evaluation and investigations for specific diseases complete the work-up.

Exercise testing can document chronotropic incompetence, conduction behaviour and the relationship between symptoms and activity. Electrophysiological study has selected indications, for example in some cases of syncope with conduction disease or for risk stratification in certain heart conditions; it is not mandatory before every implantation. Likewise, a defibrillator is not indicated on the basis of a single premature beat or a vague fear of arrhythmia. Decisions arise from the combination of diagnosis, demonstrated risk, expected benefit and alternatives.

Before the procedure, venous access, infectious and bleeding risks, renal function, antithrombotic treatment and the feasibility of follow-up are assessed. Previous catheters, procedures, congenital anomalies and dialysis needs may change the side and type of system selected. The patient must understand the aim, intended functions, possibility of shocks, need for checks and prospect of replacements. This preparation enables a proportionate choice, preventing consent from becoming mere acceptance of a procedure without understanding its therapeutic role.

Indications and device selection

In sinus node dysfunction, guidelines base the pacing indication on the relationship between bradycardia and symptoms after evaluating correctable causes. No single heart-rate value or pause duration makes a pacemaker indicated in every setting. Symptomatic chronotropic incompetence may require rate-adaptive pacing; in bradycardia–tachycardia syndrome, a device may permit necessary treatments that would otherwise worsen bradycardia. Treatment of atrial tachyarrhythmias nevertheless remains part of care.

In high-grade atrioventricular block, Mobitz II block and complete block not attributable to a reversible cause, pacing may be indicated even without symptoms because of the risk of progression or escape-rhythm instability. Lower-grade nodal forms have a different profile and require clinical correlation. A 2:1 block alone cannot distinguish Mobitz I from II and must be interpreted with attention to its site. Reflex syncope, carotid sinus hypersensitivity and block after TAVI are specific situations, with their own selection criteria and vasodepressor or timing components to consider.

In sinus rhythm, when atrioventricular synchrony must be preserved, a dual-chamber system is often suitable. In permanent atrial fibrillation, atrial pacing usually does not offer the same utility and a ventricular system tailored to the patient's needs may suffice. Selection must nevertheless account for ventricular function and anticipated pacing burden: correcting the rate with a mode that causes marked dyssynchrony may not be optimal. In sinus node dysfunction, the MOST trial found advantages of dual-chamber pacing for atrial fibrillation, heart-failure symptoms and quality of life, without significant improvement in the primary outcome of death or nonfatal stroke.

An ICD for secondary prevention is considered after cardiac arrest due to ventricular fibrillation or haemodynamically significant ventricular tachycardia when the risk is not explained by a completely reversible cause and the patient's clinical outlook allows for benefit. Particular circumstances exist in which ablation, arrhythmia type, ventricular function and underlying substrate alter the decision. Assessment cannot be reduced to the dichotomy of “arrhythmia present or absent”: recurrence probability, preventable mode of death and therapeutic options must be understood.

In primary prevention, persistent systolic dysfunction despite appropriate therapy is an important criterion in several cardiac diseases. An ejection fraction around or below 35% is a threshold used in many settings, but the indication and strength of recommendation depend on aetiology, symptoms, time since infarction or revascularization and treatment response. Reduced function during the acute phase does not automatically mean that a permanent ICD indication exists. Expected survival with acceptable functional status, frailty and non-arrhythmic mortality risk are also considered.

In cardiomyopathies and channelopathies, ejection fraction does not capture the entire risk. Fibrosis on MRI, specific genetic variants, syncope, documented arrhythmias and phenotype features may change the indication. Risk algorithms are disease-specific and should not be transferred from one cardiomyopathy to another. Drug treatment and ablation may reduce episodes but do not always replace defibrillator protection. In younger patients, prolonged exposure to revision risk makes configuration selection especially important.

CRT is indicated or considered in selected patients with heart failure, reduced systolic function and conduction delay after appropriate drug treatment. Benefit is particularly established in sinus rhythm with ejection fraction ≤35%, left bundle branch block and QRS ≥150 ms; other durations and morphologies require a more nuanced assessment. A narrow QRS without another pacing indication does not justify CRT solely on the basis of echocardiographic dyssynchrony. In atrial fibrillation, achieving a very high proportion of truly effective biventricular pacing is essential, using specific strategies if intrinsic conduction prevents this.

Conduction system pacing includes His bundle pacing and left bundle branch area pacing. It may be selected to avoid or correct consequences of conventional ventricular pacing and, in appropriate circumstances, as an alternative or rescue strategy when CRT cannot be delivered or is ineffective. Capture of conduction tissue must be documented using relevant electrocardiographic and electrophysiological criteria and distinguished from septal myocardial capture alone. Threshold stability, location of block, technical complexity and long-term evidence influence the choice.

Leadless pacemakers eliminate the chest pocket and conventional transvenous lead by implanting the system directly in the heart through venous access. Capabilities vary: some provide ventricular pacing, some use mechanical signals to synchronize it with the atrium, and other dual-chamber systems use communicating atrial and ventricular devices. The dual-chamber leadless system trial documented safety and synchronization over the early period studied, but decisions must also consider future needs, retrievability, longevity and replacement. Absence of a transvenous lead does not mean absence of complications.

A subcutaneous defibrillator avoids components within the heart and veins and represents an important option when permanent pacing, CRT or conventional ATP is unnecessary. Selection includes screening of sensed signals and risk of oversensing. In the PRAETORIAN trial, it was noninferior to a transvenous system for the composite outcome of device-related complications and inappropriate shocks in the population studied; the types of events differed between strategies. Extravascular systems with other electrode locations and modular configurations broaden the options, but capabilities and indications must be assessed for the specific technology available.

Implantation, programming and integrated treatment

Transvenous implantation involves choosing the access site, placing and securing the leads, testing sensing and capture, connecting the generator and closing the pocket. Positioning must provide electrical and mechanical stability while avoiding inappropriate tension or loops. In conventional CRT, the left ventricular lead is generally placed in a cardiac vein through the coronary sinus; anatomy, scar, thresholds and phrenic nerve stimulation can restrict the site. Epicardial, leadless and extravascular approaches have their own techniques and risks.

Prevention of complications includes antibiotics before incision, asepsis, haemostasis and an individualized antithrombotic plan. Elective implantation is deferred where possible in the presence of uncontrolled active infection. Generator replacement requires the same attention to infection risk and must not be regarded as a trivial intervention. In selected patients, an antibacterial envelope may complement prevention; it does not replace proper technique and risk-factor management.

Initial programming must be checked against the diagnosis and physiology. Minimum rate, exercise response, intervals, capture margins and sensitivity are chosen to ensure reliable treatment without unnecessarily high energy consumption. In patients with intermittent conduction, reducing ventricular pacing may help, but algorithms must not cause pauses or haemodynamically unfavourable intervals. With CRT, the central aim is effective capture and coordination, not simply keeping a nominal feature active.

In ICDs, research on therapy programming has changed clinical practice. In the primary-prevention population studied, MADIT-RIT showed that treatment at higher rates or with prolonged detection reduced inappropriate interventions compared with conventional programming. This principle does not mean disregarding slower tachycardias: detection zones must include the patient's clinical arrhythmias and account for drug effects. ATP, shock sequences and discriminators are tailored to the device and arrhythmia history.

Treatment of the underlying heart disease continues after implantation. Heart failure therapy, control of ischaemia and atrial arrhythmias, and correction of electrolytes help reduce events and hospitalizations. Recurrent ventricular tachycardias may require antiarrhythmic drugs or ablation even if the ICD terminates them effectively. A series of appropriate shocks is not a satisfactory outcome to accept without further assessment, since reducing arrhythmic burden and effects on the patient's life are also objectives.

Choosing between CRT-P and CRT-D requires distinguishing the benefit of resynchronization from the additional benefit of defibrillation. Aetiology, scarring, age, arrhythmias, comorbidities and preferences influence the decision. CRT trials have shown major benefits in selected populations; the added value of an ICD is not identical across phenotypes. The DANISH trial, which did not demonstrate a significant reduction in all-cause mortality in the overall non-ischaemic heart failure population studied, highlights the role of competing risks and patient selection without proving an absence of benefit in every non-ischaemic patient.

Indications and strategy are reassessed when the battery is replaced. Recovery of ventricular function, absence or presence of arrhythmias, progression of comorbid illness and patient wishes can change the balance. Replacement is not merely an automatic technical continuation; at the same time, improved ejection fraction does not necessarily eliminate all pre-existing arrhythmic risk. A decision requires informed discussion and documentation of the clinical reasoning.

Follow-up, further investigations and prognosis

Follow-up assesses therapeutic effectiveness and device integrity. Checks cover symptoms, wound or pocket, intrinsic rhythm, battery, thresholds, sensing, impedances and stored data. Initial values provide a reference for identifying later changes. Estimated longevity depends on device type, pacing percentages, pulse energy, high-voltage therapies and communication; it cannot be reduced to a single number of years for every patient. Replacement indicators must be managed according to the model and clinical need.

Remote monitoring may enable earlier recognition of arrhythmias and technical problems, shortening the interval between an event and evaluation. Its effectiveness requires reliable transmissions, alarm configuration and a service capable of acting on incoming data. Patients must know that severe symptoms require urgent care even if the system transmits automatically. An alert is not a complete diagnosis: electrograms and parameter trends must be interpreted before changing settings or undertaking an intervention.

ECG and echocardiography retain roles that electronic interrogation cannot replace. They permit assessment of pacing morphology, actual capture, ventricular function and regurgitation. In patients with substantial ventricular pacing or new symptoms, early recognition of deterioration is important. With CRT, lack of improvement warrants a search for correctable problems such as poor effective capture, atrial fibrillation, ectopic beats, unfavourable lead location or incomplete drug treatment. The term “nonresponse” describes a heterogeneous outcome rather than one mechanism.

Assessment during exercise is useful if breathlessness, fatigue or palpitations occur only with activity. It may reveal an inadequate chronotropic response, upper-rate behaviour, loss of synchronization or arrhythmias. In other situations, prolonged monitoring, advanced imaging or electrophysiological study is chosen according to the clinical question. The aim is to connect symptoms with rhythm and haemodynamics, avoiding parameter changes based solely on nonspecific symptoms.

Managing surgery and MRI requires a plan. Device type, pacing dependence, surgical site, potential interference and magnet response are identified. When ICD therapies are suspended, they must be restored and checked at the end of care. For MRI, classification concerns the complete system and scanning conditions; many patients can be safely scanned with appropriate protocols, but selection, programming and monitoring are necessary. The label “pacemaker carrier” alone is insufficient either to exclude a patient or to permit unrestricted MRI.

Advice and restrictions concerning daily life depend on the device, postoperative stage, heart disease and arrhythmia history. Resuming activity should protect healing and promote recovery without unjustified prolonged immobilization. Occupational exposure to electromagnetic fields may require specific assessment; having a device does not mean that every electronic appliance is dangerous. Sport and driving require consideration of syncope or shock risk, type of activity and applicable rules, which must be checked in the individual setting.

Prognosis depends on the treated condition. A pacemaker may eliminate symptoms of bradycardia and prevent events related to dangerous blocks, but does not correct every cause of syncope. ICDs reduce arrhythmic death in populations with demonstrated benefit without preventing progression of heart failure or other causes of death. CRT may improve remodelling, symptoms and survival when indicated, with variable responses. Implantation and follow-up quality determine how much of the potential benefit is actually realized.

At advanced stages of disease, goals of care and device functions are also addressed. Deactivation of shock therapies can be discussed to avoid painful interventions inconsistent with the patient's wishes; it does not necessarily mean discontinuing antibradycardia pacing. The decision requires information, consent and documentation, distinguishing the different functions. Advance planning helps keep the device aligned with clinical goals throughout the course of disease.

Complications

Early complications include bleeding and access-related injury, resulting in haematoma, pneumothorax, vascular injury or, more rarely, other procedural consequences. Haematoma can impair healing and promote infection; risk also depends on antithrombotic management. Lead dislodgement can cause loss of capture, inadequate signals or extracardiac stimulation. Postoperative assessment combines electrical parameters and anatomical investigations according to clinical suspicion.

Cardiac perforation can cause pain, effusion and tamponade. It may also become apparent after the immediate postoperative period and is not ruled out by apparently preserved electrical parameters. With leadless systems, complications involving femoral access, fixation and the cardiac wall remain possible despite the absence of a chest pocket and traditional venous lead. Each architecture therefore trades some risks for a different risk profile.

Infections may affect the wound, pocket and endovascular components. A limited incisional infection must be distinguished from infection involving the system; erosion and exposure require prompt specialist assessment. Biofilm often makes antibiotics alone insufficient when device material is involved. Removal and reimplantation strategies take account of infection extent and pacing dependence, since the need to continue electrical therapy does not remove the need for source control.

Over time, fracture, insulation or connection defects, battery depletion or generator malfunction can occur. Noise and incorrect sensing can inhibit pacing or cause inappropriate shocks; a faulty high-voltage circuit can compromise defibrillation. Alerts and monitoring are useful, but some problems are intermittent. A normal interrogation at one point therefore does not exclude every abnormality, particularly when the clinical history is suggestive.

Functional complications include pacemaker syndrome, device-related tachycardias, inadequate chronotropic response and loss of resynchronization. They can occur without hardware failure and require understanding of timing and pacing modes. Pacing-associated cardiomyopathy is a more structural consequence of dyssynchrony in susceptible patients; other causes of dysfunction must be excluded to make the diagnosis. Reprogramming may suffice in some cases, while others require a change in pacing strategy.

Transvenous leads can promote thrombosis, venous stenosis and tricuspid regurgitation. The first two may remain silent until a further procedure or cause congestion in the limb and upper venous territory; regurgitation may result from mechanical interaction with the leaflets or coexist for unrelated reasons. Establishing causation is essential before proposing extraction to improve valve function. Preserving vascular access is particularly important for patients likely to need many procedures throughout life.

Shocks and psychological burden constitute another dimension of follow-up. Fear of further interventions, anxiety and restrictions on activities can persist even when the device works correctly. Management includes explaining the event, reducing arrhythmias and unnecessary therapies, and providing appropriate support. An overall assessment of complications of implantable devices must therefore consider safety, effectiveness, cardiac function and quality of life as inseparable outcomes of the same treatment.

Bibliography
  1. Glikson M et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2021;42(35):3427–3520.
  2. Zeppenfeld K et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43(40):3997–4126.
  3. Burri H et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators. Europace. 2021;23(7):983–1008.
  4. Chung MK et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023;20(9):e17–e91.
  5. Glikson M et al. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing. Europace. 2025;27(4):euaf050.
  6. Lamas GA et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. The New England Journal of Medicine. 2002;346(24):1854–1862.
  7. Curtis AB et al. Biventricular pacing for atrioventricular block and systolic dysfunction. The New England Journal of Medicine. 2013;368(17):1585–1593.
  8. Bardy GH et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine. 2005;352(3):225–237.
  9. Cleland JGF et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England Journal of Medicine. 2005;352(15):1539–1549.
  10. Køber L et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. The New England Journal of Medicine. 2016;375(13):1221–1230.
  11. Moss AJ et al. Reduction in inappropriate therapy and mortality through ICD programming. The New England Journal of Medicine. 2012;367(24):2275–2283.
  12. Knops RE et al. Subcutaneous or Transvenous Defibrillator Therapy. The New England Journal of Medicine. 2020;383(6):526–536.
  13. Knops RE et al. A Dual-Chamber Leadless Pacemaker. The New England Journal of Medicine. 2023;388(25):2360–2370.
  14. Ferrick AM et al. 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic. Europace. 2023;25(5):euad123.
  15. Wan EY et al. Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association. Circulation. 2024;150(8):e183–e196.
  16. Kim D et al. SCMR expert consensus statement for cardiovascular magnetic resonance of patients with a cardiac implantable electronic device. Journal of Cardiovascular Magnetic Resonance. 2024;26(1):100995.
  17. Blomström-Lundqvist C et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections. Europace. 2020;22(4):515–549.
  18. Tarakji KG et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. The New England Journal of Medicine. 2019;380(20):1895–1905.
  19. Cha YM et al. 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS expert consensus statement update on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2026;23(8):e1716–e1792.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.